CLAIMS

1. A method of increasing a plasma level of tetrabenazine, alpha-dihydrotetrabenazine, or beta-dihydrotetrabenazine in a human being comprising: administering a combination comprising: 1) an enantiomeric excess of *R*-bupropion or an enantiomeric excess of *S*-bupropion, and 2) tetrabenazine, alpha-dihydrotetrabenazine, or beta-dihydrotetrabenazine to the human being daily for at least 8 consecutive days, wherein the human being is in need of treatment with tetrabenazine, alpha-dihydrotetrabenazine, or beta-dihydrotetrabenazine, and wherein the C_{max} of tetrabenazine, the C_{max} of alpha-dihydrotetrabenazine, or the C_{max} of beta-dihydrotetrabenazine is increased at least 5 fold in the human being on the eighth day as compared to the corresponding C_{max} that would be achieved when tetrabenazine, alpha-dihydrotetrabenazine, or beta-dihydrotetrabenazine is administered alone.

2. The method of claim 1, wherein administering the combination is for treating Huntington's disease or chorea associated with Huntington's disease.

3. The method of claim 1, wherein administering the combination is for treating agitation in Alzheimer's disease.

4. The method of claim 1, wherein administering the combination is for treating depression.

5. The method of claim 1, 2, 3, or 4, wherein about 100 mg to about 110 mg of the *R*-bupropion or the *S*-bupropion is administered twice a day to the human being for at least 8 consecutive days.

6. The method of claim 1, 2, 3, or 4, wherein about 90 mg to about 140 mg of the *R*-bupropion or the *S*-bupropion is administered twice a day to the human being for at least 8 consecutive days.

7. The method of claim 4, wherein the depression is treatment-resistant depression.

8. The method of claim 1, 2, 3, 4, or 7, wherein about 5 mg to about 20 mg of the tetrabenazine is administered twice a day to the human being for at least 8 consecutive days.

9. The method of claim 1, 2, 3, 4, or 7, wherein the AUC of alpha-dihydrotetrabenazine on day 8 is at least 5 times the AUC that would be achieved by administering the same amount of the tetrabenazine, the alpha-dihydrotetrabenazine, or the beta-dihydrotetrabenazine to the human being for 8 consecutive days without administering the *R*-bupropion or the *S*-bupropion.

10. The method of claim 1, 2, 3, 4, or 7, wherein the AUC of beta-dihydrotetrabenazine on day 8 is at least 15 times the AUC that would be achieved by administering the same amount of the tetrabenazine, the alpha-dihydrotetrabenazine, or the beta-dihydrotetrabenazine to the human being for 8 consecutive days without administering the *R*-bupropion or the *S*-bupropion.

11. The method of claim 1, 2, 3, 4, or 7, wherein the C_{max} of alpha-dihydrotetrabenazine on day 8 is at least twice the C_{max} that would be achieved by administering the same amount of the tetrabenazine, the alpha-dihydrotetrabenazine, or the beta-dihydrotetrabenazine to the human being for 8 consecutive days without administering the *R*-bupropion or the *S*-bupropion.

12. The method of claim 1, 2, 3, 4, or 7, wherein the C_{max} of beta-dihydrotetrabenazine on day 8 is at least 5 times the C_{max} that would be achieved by administering the same amount of the tetrabenazine, the alpha-dihydrotetrabenazine, or the beta-dihydrotetrabenazine to the human being for 8 consecutive days without administering the *R*-bupropion or the *S*-bupropion.

13. The method of claim 4, wherein the depression is major depression.

14. The method of claim 1, 2, 3, 4, 7, or 13, wherein the *R*-bupropion has an enantiomeric excess of at least 95%.

15. The method of claim 1, 2, 3, 4, 7, or 13, wherein the *S*-bupropion has an enantiomeric excess of at least 95%.

16. The method of claim 1, 2, 3, 4, 7, or 13, wherein the *R*-bupropion or the *S*-bupropion, and the tetrabenazine, the alpha-dihydrotetrabenazine, or the beta-dihydrotetrabenazine are administered in a single dosage form.

17. The method of claim 1, 2, 3, 4, 7, or 13, wherein the *R*-bupropion or the *S*-bupropion, and the tetrabenazine, the alpha-dihydrotetrabenazine, or the beta-dihydrotetrabenazine are administered in separate dosage forms.

18. The method of claim 1, 2, 3, 4, 7, or 13, wherein the *R*-bupropion or the *S*-bupropion is formulated for sustained release.

19. The method of claim 1, 2, 3, 4, 7, or 13, wherein the tetrabenazine, the alpha-dihydrotetrabenazine, or the beta-dihydrotetrabenazine is formulated for immediate release.

20. The method of claim 1, 2, 3, 4, 7, or 13, wherein the combination is orally administered to the human being.